Is there an inherent limit to acute migraine treatment efficacy?

J Headache Pain. 2009 Dec;10(6):393-4. doi: 10.1007/s10194-009-0162-y. Epub 2009 Oct 10.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Azepines / pharmacology*
  • Azepines / therapeutic use
  • Calcitonin Gene-Related Peptide Receptor Antagonists*
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / standards
  • Dipeptides / pharmacology*
  • Dipeptides / therapeutic use
  • Drug Administration Schedule
  • Endpoint Determination / methods
  • Endpoint Determination / standards
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Migraine Disorders / drug therapy*
  • Migraine Disorders / metabolism
  • Migraine Disorders / physiopathology
  • Piperazines
  • Quinazolines / pharmacology*
  • Quinazolines / therapeutic use
  • Receptors, Calcitonin Gene-Related Peptide / metabolism
  • Serotonin Receptor Agonists / pharmacology
  • Serotonin Receptor Agonists / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Tryptamines / pharmacology
  • Tryptamines / therapeutic use

Substances

  • Azepines
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Dipeptides
  • Imidazoles
  • Piperazines
  • Quinazolines
  • Receptors, Calcitonin Gene-Related Peptide
  • Serotonin Receptor Agonists
  • Tryptamines
  • telcagepant
  • olcegepant